Eli Lilly Surges After Q3 Earnings Beat, lifts Revenue Outlook

Eli Lilly reported Q3 adjusted EPS of $7.48, well above the $5.68 consensus, on revenue of $24.4 billion versus $22.58 billion expected. Mounjaro sales hit $10.7 billion, beating estimates, while Zepbound generated $5.3 billion. The company raised its full-year revenue guidance to $91-92 billion from $85-87 billion, but trimmed adjusted EPS guidance to $35-36. Shares jumped 8.4%.